Drugs / MB-dNPM1-TCR.1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06424340 | Aug 2024 → Jun 2028 expected | acute myeloid leukemia | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-dNPM1-TCR.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06424340 ↗ |
| Action | Deplete | “The dNPM1-TCR transduced T cells target specifically the HLA/dNPM1 peptide complex on the cell surface of leukemic myeloid cells and eliminate these.” NCT06424340 ↗ |
| Modality | Cell therapy | “ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR)” NCT06424340 ↗ |